Warner Chilcott (NASDAQ:WCRX) Getting Ready to Post Quarterly Results; Held Conference Call on Feb. 22 – WCRX, ACT, NVS, SHPG

Specialty pharmaceutical company Warner Chilcott Plc (NASDAQ:WCRX) reported that it will provide its fiscal Q4 and full year 2012 financial results earlier to the market opening on Friday, February 22, 2013.

The corporation will host a conference call for all interested parties on Friday, February 22, 2013 at 8:00 AM to review the results.

Warner Chilcott estimate 2013 adjusted earnings lower than analysts’ forecasts as it projects research and development costs to boost with few of its drugs moving into late-stage development.

The company would spend almost $115 million to $135 million on research and development in 2013. The corporation reported it also projects higher legal costs on a conference call with analysts but did not elaborate further.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Actavis Inc (NYSE:ACT) fell -1.45% to settle at $85.24, Novartis AG (ADR) (NYSE:NVS) moved up +0.76% to end at $69.20 while Shire PLC (ADR) (NASDAQ:SHPG) jumped +2.12% to finish at $95.67 on Friday.

Warner Chilcott Plc (NASDAQ:WCRX) last session’s volume of 7.26 million shares was surprisingly higher than its average volume of 5.83 million shares. The stock after opening at $14.36 hit high price of $14.75 and then closed at $14.59 by scoring +2.46%.

The liquidity measure in recent quarter results of the company was recorded 1.07 as current ratio. The Company had total cash of $304.00 million at hand and a book value per share as -$2.64 in the most recent quarter.

The stock’s price volatility was 2.57% for a week and 3.29% for a month as well as price volatility’s Average True Range for 14 days was 0.45 and its beta remained at 1.01.

WCRX generated revenue of $2.57 billion in the previous twelve months and earned $369.26 million. The Company showed a positive 14.34% in the net profit margin as well as in its operating margin which remained at 19.30%. Company’s annual sales growth for the past five years was 29.31%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.